Skip to main content

Terapias de RNA, inmunoterapia y diagnóstico avanzado frente a las resistencias antimicrobianas

PLEC2024-011123

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Transferencia y Colaboración
Subprogram Subprograma Estatal para impulsar la Colaboración en y entre los Sectores Público y Privado
Call Proyectos de I+D+i en Líneas Estratégicas
Call year 2024
State Plan 2024-2027 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUTO DE SALUD CARLOS III DE MADRID (ISCIII)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Evaluation of a novel lateral flow immunochromatographic assay, Certest ResisCheck® Carbapenemases, for the rapid detection and differentiation of carbapenemase in Gram-negative bacteria from bacterial culture

  • Monge Olivares, Laura
  • López-Hernández, Inmaculada
  • Fernández-Cuenca, Felipe
  • Pascual, Álvaro
  • López-Cerero, Lorena
[Objectives] Carbapenemase-producing Gram-negative bacteria represent a major clinical challenge. Rapid detection and characterization of carbapenemase group is essential for guiding therapy and for infection control. We evaluated the performance of Certest ResisCheck® Carbapenemases, a novel lateral flow immunoassay (LFIA), for detecting the main carbapenemase groups from bacterial culture., [Materials and methods] A multicentre collection of 351 well-characterized clinical Gram-negative isolates, studied by whole-genome sequencing, was tested using this assay. 57 KPC, 53 NDM, 63 VIM, 68 OXA-48-like, 64 IMP and 100 carbapenem resistant non-carbapenemase producers were included., [Results] The LFIA showed an overall sensitivity of 96.4% and specificity of 100%. The positive predictive value (PPV) was 100%, and the negative predictive value (NPV) was 91.7%. No false-positives or cross-reactions with extended-spectrum β-lactamases (ESBLs) or cephalosporinases were observed either with isolates harbouring multiple carbapenemases. Detection rates for IMP and NDM variants reached 100%. Sensitivity for KPC, OXA-like and VIM was slightly lower (93.0%, 95.6% and 96.8%, respectively). Nine false-negative results were observed: KPC-31 (n = 4), VIM-63 (n = 2) and OXA-1054-producing (n = 3) isolates. Increasing the bacterial inoculum managed to obtain a positive result for KPC-31 and VIM-63, but OXA-1054 remained undetected., [Conclusions] Certest ResisCheck® Carbapenemases is a rapid, accurate, and reliable tool for detecting carbapenemases in clinical settings. While some rare variants may escape detection, its strong performance across diverse bacterial species supports its use as part of routine diagnostics to guide timely antimicrobial therapy and control the spread of resistance., This work was funded by MICIU/AEI/10.13039/501100011033/FEDER and European Union ‘NextGenerationEU’/PRTR’ (PLEC2021-007972), and by MICIU/AEI/10.13039/501100011033/FEDER, European Union and Ministry of Science, Innovation and Universities, the Agency and the European Regional Development Fund (PLEC2024-011123)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Genome assembly and functional predation analysis of novel Bdellovibrio isolates from human gut microbiota

  • Romero-Rivera, Mario
  • Fernández de Bobadilla, Miguel D.
  • Beltrán, María
  • Del Campo, Rosa
  • Avendaño-Ortiz, José
  • Herencias, Cristina
Predatory bacteria of the Bdellovibrio and like organisms (BALOs) have long been postulated as living antimicrobials, yet their occurrence and ecological roles within human-associated microbiota have remained uncertain due to the absence of culturable human-derived isolates. Here, we report the first successful isolation and comprehensive characterization of viable Bdellovibrio bacteriovorus from human fecal samples., The author(s) declared that financial support was received for this work and/or its publication. Work in the Metagenomics lab is supported by PRECICOLON P2022/BMD-7212 from Comunidad de Madrid, METOXISAN project from Fundación Mutua Madrileña, END-RAM PLEC2024011123 project by Agencia Estatal de Investigación and MePRAM PMP22/00092 funded by Instituto de Salud Carlos III. Work of MR-R was supported by Fundación Carolina (C2022). During implementation of this study, MD-F was supported by the Instituto de Salud Carlos III (pFIS F19/00366). CH is supported by the European Union (ERC, HorizonGT, 101077809), PI23/01945 by the Carlos III Health Institute (ISCIII), and FERP-2024-182 (2024/0357) funded by Fundación Eugenio Rodríguez Pascual., Peer reviewed